MSH3 and neoplasm: This demonstrates their potential value in addressing tumours exhibiting an MDR phenotype because of MRP1 overexpression, supporting the sequential administration of calcitriol and additional anticancer drugs to treat MRP1-mediated MDR in clinical chemotherapy [123].